simendan has been researched along with Heart Disease, Ischemic in 44 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (11.36) | 18.2507 |
| 2000's | 23 (52.27) | 29.6817 |
| 2010's | 15 (34.09) | 24.3611 |
| 2020's | 1 (2.27) | 2.80 |
| Authors | Studies |
|---|---|
| Aalto-Setälä, K; Gaballah, M; Kallio, P; Kreutzer, J; Mäki, AJ; Penttinen, K | 1 |
| Irving, M; Klein, BA; Li, L; Reiz, B; Robertson, IM; Sun, YB; Sykes, BD | 1 |
| Alkan, M; Arslan, M; Erkent, FD; Kılıç, Y; Kucuk, A; Mardin, B; Oktar, GL; Özer, A; Sezen, ŞC; Tosun, M; Ünal, Y | 1 |
| Abrahamsson, P; Axelsson, B; Gupta, A; Haney, M; Johansson, G; Tydén, H; Wouters, P | 1 |
| Guo, M; Jia, Z; Liang, HQ; Song, Y; Zhang, LY; Zhang, YQ | 1 |
| Beutlhauser, T; Erb, J; Feldheiser, A; Grubitzsch, H; Schuster, B; Spies, C; Treskatsch, S | 1 |
| Arslan, M; Demir Amac, N; Elmas, C; Erer, D; Goktas, G; Iriz, E; Oktar, GL; Tatar, T; Zor, MH | 1 |
| Axelsson, B; Gupta, A; Häggmark, S; Haney, M; Johansson, G; Svenmarker, S; Tydén, H; Wouters, P | 1 |
| Kapralou, A; Katsaragakis, S; Markogiannakis, H; Theodorou, D; Toufektzian, L | 1 |
| Akilli, A; Akin, M; Duygu, H; Ergene, O; Erturk, U; Nalbantgil, S; Nazli, C; Ozerkan, F; Zoghi, M | 1 |
| Akilli, A; Akin, M; Duygu, H; Nalbantgil, S; Ozerkan, F; Yildiz, A; Zoghi, M | 1 |
| Kurt, IH | 1 |
| Baumert, JH; Hein, M; Roehl, AB; Rossaint, R; Scherer, K; Steendijk, P | 1 |
| Algotsson, L; Liao, Q; Linnér, R; Metzsch, C; Steen, S | 1 |
| Caimmi, PP; Cattaneo, M; Grossini, E; Mary, DA; Molinari, C; Platini, F; Tessitore, L; Uberti, F; Vacca, G; Valente, G | 1 |
| Apostolakis, S; Lazaridis, K; Spandidos, DA; Tzoras, S; Zaravinos, A | 1 |
| Caimmi, PP; Grossini, E; Mary, DA; Micalizzi, E; Molinari, C; Uberti, F; Vacca, G; Valente, G | 1 |
| Beggino, C; Caimmi, PP; Crosio, E; Giustini, G; Grossini, E; Kapetanakis, EI; Micalizzi, E; Molinari, C; Reposo, G; Vacca, G | 1 |
| Bersani, I; Conti, G; De Carolis, MP; De Rosa, G; Pardeo, M; Piastra, M; Romagnoli, C; Stival, E; Tempera, A | 1 |
| Allegaert, K; Thewissen, L | 1 |
| Arocas-Casañ, V; Blázquez-Álvarez, MJ; Cárceles-Barón, MD; de la Rubia-Nieto, A; Fernández de Palencia-Espinosa, MA | 1 |
| Leprán, I; Papp, JG | 1 |
| Bernhard-Abt, A; Ettner, U; Heimisch, W; Lange, R; Mendler, N; Schad, H; Tassani, P | 1 |
| Pieske, B | 1 |
| Boldt, J; Kirchner, J; Lehmann, A | 1 |
| Camara, AK; Chen, Q; Novalija, E; Rhodes, SS; Riess, ML; Stowe, DF | 1 |
| Nieminen, MS; Sandell, EP | 1 |
| Battagliese, A; Bucciarelli Ducci, C; Celotto, A; De Luca, L; Fedele, F; Palombaro, GL; Proietti, P | 1 |
| Kleber, FX; Lehtonen, LA; Sonntag, S; Sundberg, S | 1 |
| Bonnefoy, E; Trindade, PT | 1 |
| Brussel, T; Ellger, BM; Schmidt, C; Van Aken, HK; Zahn, PK | 1 |
| Colucci, WS; De Luca, L; Gheorghiade, M; Massie, BM; Nieminen, MS | 1 |
| Algotsson, L; Liao, Q; Metzsch, C; Steen, S | 1 |
| Bröking, K; Ertmer, C; Lange, M; Morelli, A; Rehberg, S; Van Aken, H; Westphal, M | 1 |
| Akilli, A; Akin, M; Duygu, H; Ergene, O; Nalbantgil, S; Nazli, C; Ozerkan, F; Zoghi, M | 1 |
| Auriti, A; Cianfrocca, C; Guido, V; Li, X; Mercuro, G; Pasceri, V; Pelliccia, F; Richichi, G; Santini, M | 1 |
| Behrends, M; Brendt, P; Peters, J | 1 |
| Boldt, J; Isgro, F; Kiessling, AH; Lehmann, A; Thaler, E; Zeitler, C | 1 |
| Acar, D; Klaus, W; Rump, AF | 1 |
| Lilleberg, J; Nieminen, MS; Sundberg, S | 1 |
| Du Toit, EF; McCarthy, J; Muller, CA; Opie, LH | 1 |
| Ball, NA; Bodi, A; Edes, I; Kristof, E; Papp, Z; Szigeti, G; Walsh, RA | 1 |
| Afanas'ev, SA; Karpov, RS; Timofeev, VIu | 1 |
| Datz, N; Hasenfuss, G; Janssen, PM; Zeitz, O | 1 |
7 review(s) available for simendan and Heart Disease, Ischemic
| Article | Year |
|---|---|
Use of levosimendan in patients with ischemic heart disease following mechanical reperfusion.
Topics: Cardiotonic Agents; Coronary Artery Disease; Humans; Hydrazones; Myocardial Ischemia; Myocardial Reperfusion; Myocardial Stunning; Pyridazines; Simendan; Vasodilator Agents | 2009 |
The role of Ca++-sensitizers for the treatment of heart failure.
Topics: Calcium; Cardiotonic Agents; Chronic Disease; Clinical Trials as Topic; Dobutamine; Heart Failure; Hemodynamics; Humans; Hydrazones; Myocardial Ischemia; Pyridazines; Simendan | 2003 |
Considerations on the efficacy and safety of levosimendan in ischemic heart failure.
Topics: Calcium Channels, L-Type; European Union; Heart Failure; Humans; Hydrazones; Morbidity; Myocardial Contraction; Myocardial Ischemia; Pyridazines; Simendan; Treatment Outcome; United States; Vasodilator Agents | 2003 |
New positive inotropic agents in the treatment of left ventricular dysfunction.
Topics: Cardiotonic Agents; Diastole; Heart Failure; Humans; Hydrazones; Milrinone; Myocardial Ischemia; Phosphodiesterase Inhibitors; Pyrazines; Pyridazines; Quinolines; Simendan; Ventricular Dysfunction, Left; Ventricular Function, Left | 2004 |
[Levosimendan, a revolution in the world of inotropic agents?].
Topics: Anti-Arrhythmia Agents; Heart Failure; Hemodynamics; Humans; Hydrazones; Myocardial Contraction; Myocardial Ischemia; Pyridazines; Simendan | 2005 |
Evidence-based use of levosimendan in different clinical settings.
Topics: Administration, Oral; Adult; Arrhythmias, Cardiac; Cardiotonic Agents; Child; Heart Failure; Humans; Hydrazones; Intraoperative Care; Myocardial Ischemia; Pyridazines; Randomized Controlled Trials as Topic; Shock, Cardiogenic; Simendan | 2006 |
[Role of Levosimendan in intensive care treatment of myocardial insufficiency].
Topics: Calcium; Cardiac Output, Low; Cardiotonic Agents; Critical Care; Humans; Hydrazones; Myocardial Ischemia; Postoperative Care; Pyridazines; Simendan | 2007 |
9 trial(s) available for simendan and Heart Disease, Ischemic
| Article | Year |
|---|---|
Efficacy of intravenous levosimendan in patients with heart failure complicated by acute myocardial infarction.
Topics: Cardiotonic Agents; Female; Heart Failure; Humans; Hydrazones; Infusions, Intravenous; Male; Middle Aged; Myocardial Ischemia; Pyridazines; Simendan; Single-Blind Method; Treatment Outcome | 2014 |
Influence of levosimendan on organ dysfunction in patients with severely reduced left ventricular function undergoing cardiac surgery.
Topics: Aged; Aged, 80 and over; Blood Pressure; Cardiomyopathies; Cardiotonic Agents; Coronary Artery Bypass; Double-Blind Method; Enoximone; Female; Humans; Hydrazones; Infusions, Intravenous; Male; Middle Aged; Myocardial Ischemia; Norepinephrine; Prospective Studies; Pyridazines; Simendan; Stroke Volume; Treatment Outcome; Vasoconstrictor Agents; Ventricular Dysfunction, Left | 2014 |
Effects of levosimendan on left atrial functions in patients with ischemic heart failure.
Topics: Aged; Atrial Function, Left; Blood Pressure; Cardiotonic Agents; Dobutamine; Female; Heart Failure; Humans; Hydrazones; Male; Middle Aged; Myocardial Ischemia; Pyridazines; Simendan; Stroke Volume; Ventricular Function, Left; Ventricular Pressure | 2008 |
Comparison of ischemic side effects of levosimendan and dobutamine with integrated backscatter analysis.
Topics: Cardiotonic Agents; Dobutamine; Electrocardiography; Female; Humans; Hydrazones; Image Interpretation, Computer-Assisted; Injections, Intravenous; Male; Middle Aged; Myocardial Ischemia; Predictive Value of Tests; Pyridazines; Radiography; Simendan; Stroke Volume; Treatment Outcome; Ventricular Function, Left | 2009 |
Levosimendan reduces plasma cell-free DNA levels in patients with ischemic cardiomyopathy.
Topics: Aged; Anti-Arrhythmia Agents; Biomarkers; Cardiomyopathies; DNA; Female; Heart Failure; Humans; Hydrazones; Male; Middle Aged; Myocardial Ischemia; Pyridazines; Simendan; Ventricular Dysfunction, Left | 2011 |
The calcium sensitizer levosimendan improves the function of stunned myocardium after percutaneous transluminal coronary angioplasty in acute myocardial ischemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Cardiac Volume; Cardiotonic Agents; Coronary Circulation; Coronary Disease; Diastole; Double-Blind Method; Female; Humans; Hydrazones; Male; Middle Aged; Myocardial Ischemia; Myocardial Stunning; Pyridazines; Simendan; Systole; Treatment Outcome; Vasodilation; Vasodilator Agents; Ventricular Function, Left; Ventricular Pressure | 2004 |
Effect of levosimendan on E/E' ratio in patients with ischemic heart failure.
Topics: Aged; Cardiotonic Agents; Dobutamine; Echocardiography, Doppler; Female; Heart Failure; Humans; Hydrazones; Male; Middle Aged; Myocardial Ischemia; Prospective Studies; Pyridazines; Simendan; Single-Blind Method | 2008 |
Levosimendan allows detection of contractile reserve in patients with chronic ischaemic left ventricular dysfunction and non-diagnostic dobutamine echocardiography.
Topics: Cardiotonic Agents; Dobutamine; Echocardiography; Humans; Hydrazones; Myocardial Contraction; Myocardial Ischemia; Pyridazines; Simendan; Ventricular Dysfunction, Left | 2007 |
Dose-range study of a new calcium sensitizer, levosimendan, in patients with left ventricular dysfunction.
Topics: Aged; Cardiotonic Agents; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Electrocardiography; Hemodynamics; Humans; Hydrazones; Infusions, Intravenous; Middle Aged; Myocardial Ischemia; Phosphodiesterase Inhibitors; Placebos; Pulmonary Circulation; Pyridazines; Simendan; Vascular Resistance; Ventricular Function, Left | 1995 |
28 other study(ies) available for simendan and Heart Disease, Ischemic
| Article | Year |
|---|---|
Cardiac Ischemia On-a-Chip: Antiarrhythmic Effect of Levosimendan on Ischemic Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cells, Cultured; Humans; Hypoxia; Induced Pluripotent Stem Cells; Ischemia; Lab-On-A-Chip Devices; Myocardial Ischemia; Myocytes, Cardiac; Simendan | 2022 |
Reversible Covalent Reaction of Levosimendan with Cardiac Troponin C in Vitro and in Situ.
Topics: Animals; Calcium Signaling; Cysteine; Humans; Hydrazones; Hydrogen-Ion Concentration; Myocardial Ischemia; Myofibrils; Pyridazines; Simendan; Swine; Troponin C | 2018 |
Assessment of the effects of levosimendan and thymoquinone on lung injury after myocardial ischemia reperfusion in rats.
Topics: Animals; bcl-2-Associated X Protein; Benzoquinones; Hydrazones; Immunohistochemistry; Injections, Intraperitoneal; Lung Injury; Male; Myocardial Ischemia; Myocardial Reperfusion Injury; Proto-Oncogene Proteins c-bcl-2; Pyridazines; Rats; Rats, Wistar; Simendan | 2018 |
Milrinone and levosimendan during porcine myocardial ischemia -- no effects on calcium overload and metabolism.
Topics: Animals; Calcium; Calcium Radioisotopes; Cardiotonic Agents; Drug Evaluation, Preclinical; Energy Metabolism; Glucose; Glycolysis; Heart Ventricles; Hemodynamics; Hydrazones; Infusions, Intravenous; Ion Transport; Microdialysis; Milrinone; Myocardial Ischemia; Myocytes, Cardiac; Oxygen Consumption; Premedication; Pyridazines; Random Allocation; Simendan; Sus scrofa; Swine | 2013 |
The histopathological effects of levosimendan on liver injury induced by myocardial ischemia and reperfusion.
Topics: Acute Lung Injury; Animals; Disease Models, Animal; Hydrazones; Liver; Male; Myocardial Ischemia; Myocardial Reperfusion Injury; Pyridazines; Rats; Rats, Wistar; Simendan; Vasodilator Agents | 2015 |
Effects of Combined Milrinone and Levosimendan Treatment on Systolic and Diastolic Function During Postischemic Myocardial Dysfunction in a Porcine Model.
Topics: Animals; Cardiotonic Agents; Diastole; Disease Models, Animal; Drug Therapy, Combination; Hydrazones; Milrinone; Myocardial Ischemia; Myocardial Reperfusion Injury; Myocardial Stunning; Pyridazines; Recovery of Function; Simendan; Sus scrofa; Systole; Time Factors; Ventricular Dysfunction, Left; Ventricular Function, Left; Ventricular Pressure | 2016 |
Perioperative cardiac evaluation: the importance of cardiac failure management.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Cardiotonic Agents; Diuretics; Heart Failure; Humans; Hydrazones; Myocardial Ischemia; Postoperative Complications; Pyridazines; Simendan | 2008 |
Anti-ischemic effects of inotropic agents in experimental right ventricular infarction.
Topics: Animals; Blood Gas Analysis; Cardiotonic Agents; Dobutamine; Female; Heart Ventricles; Hemodynamics; Hydrazones; Inflammation Mediators; Milrinone; Myocardial Infarction; Myocardial Ischemia; Myocarditis; Myocardium; Myoglobin; Neutrophil Infiltration; Pyridazines; Simendan; Swine; Troponin T | 2009 |
Levosimendan cardioprotection in acutely beta-1 adrenergic receptor blocked open chest pigs.
Topics: Adrenergic beta-Antagonists; Animals; Cardiotonic Agents; Clinical Protocols; Female; Glucose; Glycerol; Hemodynamics; Hydrazones; Lactic Acid; Male; Metoprolol; Microdialysis; Myocardial Ischemia; Myocardial Reperfusion Injury; Pyridazines; Pyruvic Acid; Simendan; Swine; Thoracic Surgical Procedures; Treatment Outcome | 2010 |
Modulation of programmed forms of cell death by intracoronary levosimendan during regional myocardial ischemia in anesthetized pigs.
Topics: Anesthesia; Animals; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; bcl-2-Associated X Protein; Blood Pressure; Cardiotonic Agents; Coronary Circulation; Cytochromes c; Gene Expression; Heart; Heart Rate; Hydrazones; In Situ Nick-End Labeling; Microtubule-Associated Proteins; Myocardial Ischemia; Myocardium; Necrosis; Proto-Oncogene Proteins c-bcl-2; Pyridazines; Simendan; Sus scrofa; Venous Pressure; Ventricular Function, Left | 2010 |
Intracoronary levosimendan prevents myocardial ischemic damages and activates survival signaling through ATP-sensitive potassium channel and nitric oxide.
Topics: Animals; Blotting, Western; Cardiotonic Agents; Hydrazones; Infusions, Intralesional; KATP Channels; Myocardial Ischemia; Myocardial Reperfusion Injury; Nitric Oxide; Pyridazines; Signal Transduction; Simendan; Survival Analysis; Swine | 2011 |
Management of acute cardiac failure by intracoronary administration of levosimendan.
Topics: Acute Disease; Aged; Aged, 80 and over; Blood Pressure; Cardiac Surgical Procedures; Cardiopulmonary Bypass; Cardiotonic Agents; Female; Heart; Heart Failure; Heart Rate; Hemodynamics; Humans; Hydrazones; Injections, Intra-Arterial; Injections, Intravenous; Male; Middle Aged; Myocardial Infarction; Myocardial Ischemia; Pyridazines; Simendan; Vascular Resistance; Ventricular Function, Left | 2011 |
Levosimendan in two neonates with ischemic heart failure and pulmonary hypertension.
Topics: Cardiotonic Agents; Female; Heart Failure; Humans; Hydrazones; Hypertension, Pulmonary; Infant, Newborn; Male; Myocardial Ischemia; Pyridazines; Simendan; Treatment Outcome | 2012 |
Inotropic support in the NICU: ever more compounds in search of guidance? Commentary on J. Esch et al.: differential hemodynamic effects of levosimendan in a porcine model of neonatal hypoxia-reoxygenation (Neonatology 2012;101:192–200) and M.P. De Caroli
Topics: Animals; Cardiac Output; Cardiotonic Agents; Female; Fetal Hypoxia; Heart Failure; Humans; Hydrazones; Hypertension, Pulmonary; Male; Myocardial Ischemia; Oxygen; Pyridazines; Simendan; Swine | 2012 |
[Retrospective descriptive study about the use of levosimendan in children undergoing surgical correction for congenital heart disease].
Topics: Cardiotonic Agents; Child, Preschool; Comorbidity; Compassionate Use Trials; Coronary Circulation; Down Syndrome; Drug Evaluation; Female; Heart Defects, Congenital; Hemodynamics; Humans; Hydrazones; Hypotension; Infant; Infant, Newborn; Kaplan-Meier Estimate; Male; Myocardial Ischemia; Postoperative Complications; Potassium Channels; Pyridazines; Retrospective Studies; Salvage Therapy; Simendan; Tachycardia | 2012 |
Effect of long-term oral pretreatment with levosimendan on cardiac arrhythmias during coronary artery occlusion in conscious rats.
Topics: Administration, Oral; Animals; Arrhythmias, Cardiac; Cardiotonic Agents; Consciousness; Coronary Disease; Dose-Response Relationship, Drug; Electrocardiography; Heart; Heart Rate; Hydrazones; Male; Myocardial Ischemia; Pyridazines; Rats; Rats, Sprague-Dawley; Simendan; Time Factors | 2003 |
Effect of the calcium sensitizer levosimendan on the performance of ischaemic myocardium in anaesthetised pigs.
Topics: Anesthesia; Animals; Cardiac Output; Coronary Stenosis; Coronary Vessels; Female; Heart Rate; Hemodynamics; Hydrazones; Injections, Intravenous; Male; Myocardial Contraction; Myocardial Ischemia; Pharmaceutical Vehicles; Pyridazines; Regional Blood Flow; Simendan; Swine; Vasodilator Agents; Venous Pressure | 2002 |
Levosimendan in regional myocardial ischemia.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Arrhythmias, Cardiac; Cardiac Output; Cardiotonic Agents; Coronary Stenosis; Coronary Vessels; Cyclic Nucleotide Phosphodiesterases, Type 3; Heart Rate; Hemodynamics; Humans; Hydrazones; Myocardial Contraction; Myocardial Ischemia; Phosphodiesterase Inhibitors; Potassium Channel Blockers; Pyridazines; Regional Blood Flow; Simendan; Swine; Vasodilator Agents; Venous Pressure | 2002 |
Cardiotonic drugs differentially alter cytosolic [Ca2+] to left ventricular relationships before and after ischemia in isolated guinea pig hearts.
Topics: Animals; Calcium; Cardiotonic Agents; Cytosol; Digoxin; Dopamine; Guinea Pigs; Hydrazones; Myocardial Ischemia; Perfusion; Pyridazines; Random Allocation; Simendan; Ventricular Pressure | 2003 |
Levosimendan: a promising treatment for myocardial stunning?
Topics: Cardiotonic Agents; Facial Neoplasms; Humans; Hydrazones; Male; Middle Aged; Myocardial Ischemia; Myocardial Stunning; Postoperative Complications; Pyridazines; Simendan | 2006 |
Levosimendan cardioprotection reduces the metabolic response during temporary regional coronary occlusion in an open chest pig model.
Topics: Animals; Cardiac Output; Cardiotonic Agents; Coronary Circulation; Glucose; Hydrazones; Infusions, Intravenous; Lactic Acid; Microdialysis; Myocardial Contraction; Myocardial Ischemia; Myocardial Reperfusion; Myocardial Reperfusion Injury; Myocardium; Pyridazines; Pyruvic Acid; Simendan; Sus scrofa | 2007 |
Myocardial stunning following no flow ischaemia is diminished by levosimendan or cariporide, without benefits of combined administration.
Topics: Analysis of Variance; Animals; Anti-Arrhythmia Agents; Guanidines; Guinea Pigs; Hydrazones; In Vitro Techniques; Male; Myocardial Ischemia; Myocardial Stunning; Prospective Studies; Pyridazines; Random Allocation; Simendan; Sulfones | 2008 |
Levosimendan in patients with acute myocardial ischaemia undergoing emergency surgical revascularization.
Topics: Acute Disease; Aged; Anti-Arrhythmia Agents; Blood Pressure; Case-Control Studies; Catecholamines; Cohort Studies; Coronary Artery Bypass; Emergencies; Female; Heart Rate; Humans; Hydrazones; Infusions, Intravenous; Intra-Aortic Balloon Pumping; Length of Stay; Male; Middle Aged; Monitoring, Intraoperative; Myocardial Ischemia; Myocardial Revascularization; Pyridazines; Respiration, Artificial; Retrospective Studies; Shock, Cardiogenic; Simendan; Survival Rate; Vascular Resistance | 2008 |
A quantitative comparison of functional and anti-ischaemic effects of the phosphodiesterase-inhibitors, amrinone, milrinone and levosimendan in rabbit isolated hearts.
Topics: Amrinone; Animals; Cardiotonic Agents; Coronary Circulation; Electric Stimulation; Heart; Heart Rate; Hydrazones; In Vitro Techniques; Male; Milrinone; Myocardial Ischemia; Myocardium; NAD; Phosphodiesterase Inhibitors; Pyridazines; Pyridones; Rabbits; Simendan; Vasodilation; Ventricular Pressure | 1994 |
Levosimendan: effects of a calcium sensitizer on function and arrhythmias and cyclic nucleotide levels during ischemia/reperfusion in the Langendorff-perfused guinea pig heart.
Topics: Adenosine Triphosphate; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Calcium Channel Agonists; Calcium Channel Blockers; Cyclic AMP; Cyclic GMP; Dobutamine; Glyburide; Guinea Pigs; Heart; Hydrazones; In Vitro Techniques; L-Lactate Dehydrogenase; Lactic Acid; Myocardial Contraction; Myocardial Ischemia; Myocardial Reperfusion Injury; Myocardium; Nucleotides, Cyclic; Phosphocreatine; Pyridazines; Simendan; Stereoisomerism | 1999 |
The effects of levosimendan on the left ventricular function and protein phosphorylation in post-ischemic guinea pig hearts.
Topics: Animals; Cardiotonic Agents; Cyclic AMP; Guinea Pigs; Hydrazones; Male; Myocardial Ischemia; Myocardial Stunning; Myocardium; Phosphorylation; Proteins; Pyridazines; Simendan; Ventricular Function, Left | 1999 |
[Troponin component of the cardiotropic effect of levosimendan on the isolated myocardium from patients with chronic coronary insufficiency].
Topics: Adrenergic beta-Agonists; Cardiotonic Agents; Chronic Disease; Epinephrine; Heart; Humans; Hydrazones; In Vitro Techniques; Middle Aged; Myocardial Contraction; Myocardial Ischemia; Pyridazines; Simendan; Stimulation, Chemical | 1999 |
Levosimendan improves diastolic and systolic function in failing human myocardium.
Topics: Cardiotonic Agents; Diastole; Heart; Humans; Hydrazones; Myocardial Ischemia; Myocardium; Pyridazines; Simendan; Systole | 2000 |